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ABSTRACT
Objectives: To seek community pharmacists’ perception
on use, safety and possible effectiveness of e-cigarettes
as quit smoking tools, and their future regulation.
Setting: A survey of a sample of 154 community
pharmacies across London, UK.
Context: E-cigarettes have exclusively established
themselves in the market through consumers-led
demand. To date, e-cigarettes still remain unregulated
and can be easily purchased in shops, over the
internet, but more controversially also in pharmacies in
the UK. Pharmacists find themselves with a shortage
of information on their safety and efficacy, and may
experience an ethical dilemma when consulted by
patients/customers.
Key findings: Response rate: 60% (n=92).
Independent pharmacies accounted for 90% of the
sample. The majority of participants (73%) sell
e-cigarettes. A minority of participants (20%) have
been presented with adverse effects such as cough
and dry mouth. As possible reasons for their use,
pharmacists ranked ‘aid in stop smoking’ as the most
important (56%), with ‘cheaper alternative’ (43%) and
‘social/recreational use’ (31%) being the least important
ones. Safety issues were raised as statements such as
‘e-liquid in cartridges may be toxic’ were agreed by 52%
of respondents. The majority of pharmacists (97%) were
supportive of e-cigarettes being regulated, expressing
current concerns regarding excipients (42%) and
nicotine content (34%). Participants indicated that they
would require training in the form of information packs
(88%), online tutorials (67%), continuous professional
development (CPD) workshops (43%) to cover safety,
counselling, dosage instructions, adverse effects and
role in the smoking cessation care pathway in the future.
Conclusions: Pharmacists expressed concerns about
the safety of e-cigarettes, especially regarding the
amounts of excipients and nicotine as these still remain
unregulated. Currently, there are no guidelines for
pharmacists regarding e-cigarettes. Community
pharmacists look forward to regulations so to conduct
their duties in a more confident and legislated fashion.
INTRODUCTION
The e-cigarettes market has drastically
increased with an estimated 1.3 million users
in the UK only: estimated to be worth £340
million by 2015.1 E-cigarettes have exclusively
established themselves in the market through
consumers-led demand. Their tar-free tech-
nology enlists their status as being ‘safer’ than
conventional cigarettes, hence their evident
peaking popularity. To date, e-cigarettes have
ducked the advertising bans imposed on all
tobacco products, even though broadcasts
have in some occasions been perceived
as ‘glamorizing smoking and promoting
e-cigarettes as a safe new lifestyle choice to
young people’.2 E-cigarettes may in fact consti-
tute a ‘gateway’ to smoking for nonusers of
tobacco, especially adolescents.3–5 Coupled
with the controversy regarding safety of the
additives and ﬂavours, healthcare profes-
sionals are still undecided regarding their use.
In 2013, the Medicines and Healthcare
products Regulatory Agency (MHRA)
announced that e-cigarettes will be regulated
by 2016;6 this was then followed by the
European parliament voting for a dual-
supply route: they could be regulated as
Strengths and limitations of this study
▪ This is the first study investigating the commu-
nity pharmacists’ perception on the use, safety
and possible effectiveness of e-cigarettes as quit
smoking tools, and their future regulation.
▪ Community pharmacists play an important role in
the UK healthcare system as they work at the direct
interface with patients and members of the public
and due to their accessibility are often the first port
of call for smoking cessation. Therefore, their per-
ceptions about e-cigarettes may influence uptake
and support.
▪ Despite having a substantial number of respon-
dents, this study is limited to pharmacies in the
Greater London area.
▪ Follow-up studies seeking community pharma-
cists’ perception on a national scale may be
needed to gauge concerns and to better inform
regulators.
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either medicinal products (if marketed as quitting aids)
or tobacco products.2 In the meanwhile, e-cigarettes
remain unregulated products that can be easily pur-
chased not only in shops, supermarkets and over the
internet, but more controversially also in big chain7 and
independent community pharmacies. Chief pharmaceut-
ical ofﬁcers in the UK unanimously expressed concern
over pharmacies selling e-cigarettes8 warning pharmacy
staff not to present e-cigarettes as having any therapeutic
beneﬁt until the MHRA licences individual e-cigarettes
products. In the meanwhile, pharmacists shall continue
advising patients on the beneﬁts of using evidence-based
products such as nicotine replacement therapies (NRTs),
which have been tested and proved safe. In August 2015,
a report commissioned by Public Health England indi-
cated that e-cigarettes are around 95% safer than tobacco
smoking as many chemicals present in smoke are absent
in the e-cigarettes’ vapours.9 In November of the same
year, the MHRA in the UK licenced British American
Tobacco’s ﬁrst-generation e-Voke.
While most of the works currently in the literature
focus on the effectiveness of e-cigarettes, little can be
found regarding how healthcare professionals perceive
the current use, status and effectiveness of these devices.
In an effort to assess the extent to which health profes-
sionals perceive e-cigarettes as a positive or negative
development and needs for guidance, Hiscock et al10
surveyed 587 practitioners in 2011 and 705 in 2013.
Despite the majority of respondents increasingly indi-
cated e-cigarettes as a ‘good thing’, they found no clear
evidence they viewed e-cigarettes having an important
place in smoking cessation services. Practitioners still
expressed concerns in terms of safety or efﬁcacy of
e-cigarettes for smoking cessation. Also, this study sug-
gests that patients ask important questions about these
products and practitioners felt that the guidance for
staff and patients was not satisfactory.10 It is therefore
unclear whether guidance currently provided to health-
care professional is satisfactory. To further feed this un-
certainty, a survey11 of members of The British Thoracic
Oncology Group showed that only a minority of respon-
dents (21.0%) were conﬁdent in providing advice to
patients with lung cancer over the use of e-cigarettes,
with nurses reporting lower levels of conﬁdence.
In the literature, there is mixed evidence regarding
the potential of e-cigarettes to serve as quit smoking
aids. Etter et al12 reported that e-cigarettes may contrib-
ute to prevention of relapse in former smokers and
smoking cessation in current smokers, and they also
showed that 81% of those vaping (ie, using e-cigarettes)
daily were still vaping after 1 year. The latter datum indi-
cates that people may end up replacing tobacco with e-
cigarettes, with still unclear, potential long-term expos-
ure consequences.13 Siegel et al14 analysed abstinence
rates via an online-based survey and reported that 48.8%
of e-cigarette users achieved abstinence for a certain
length of time and 34.3% reached complete abstinence
at 6 months. More recently, Brown et al15 surveyed 5863
adults who had smoked within the previous 12 months
and made at least one quit attempt during that period
with either an e-cigarette only (7.9%), over-the-counter
NRT (32.8%) or no aid (59.3%). When measuring self-
reported abstinence, they observed that the odds of non-
smoking in users of e-cigarettes were 1.63 times higher
compared with users of NRT and 1.61 times higher com-
pared with those using no aid. These results are remark-
able because considering the large sample size of the
study, it indicates that e-cigarettes may constitute a viable
option for smokers to quit without the support of health
professionals. Conversely, Bullen et al16 conducted a ran-
domised controlled trial to evaluate e-cigarettes for
smoking cessation against placebo e-cigarettes and
patches and found that e-cigarettes were only ‘modestly
effective’ at helping smokers to quit, with similar achieve-
ment of abstinence as with nicotine patches. In a
12-month randomised controlled trial on 300 smokers
not intending to quit, Caponnetto et al17 documented
smoking reduction in 22.3% and 10.3%, and complete
abstinence from tobacco smoking in 10.7% and 8.7% of
participants at weeks 12 and 52, respectively. Additionally,
Ling et al18 followed 949 people who reported their
smoking habits through an online survey and ‘found that
there was no difference in the rate of quitting between
smokers who used an e-cigarette and those who did not’.
The current General Pharmaceutical Council’s pos-
ition on the sale of e-cigarettes in registered pharma-
cies19 and the Royal Pharmaceutical Society recommend
that e-cigarettes should not be sold or advertised by
pharmacies.20 There have been reports of pharmacists
not adhering to this recommendation.21 The current
lack of guidance on e-cigarettes for pharmacists and the
mixed evidence regarding their efﬁcacy may result in
pharmacists having limited conﬁdence in advising
patients over the safety and efﬁcacy of e-cigarettes. This
work aims at exploring community pharmacists’ percep-
tion on the use, safety and possible effectiveness of
e-cigarettes as quit smoking tools, and their future regu-
lation. We hypothesised that pharmacists have concerns
regarding the safety of e-cigarettes and are in favour of
future regulations, which will ensure patients’ safety.
METHOD
This is a quantitative study involving a survey of commu-
nity pharmacists in Greater London. Ethics approval was
sought and obtained by the Kingston University Ethics
Committee.
Participants and recruitment
Pharmacies were selected by convenience sampling to
include small independent pharmacies and big chains.
The selection of pharmacies was carried out without
knowing whether e-cigarettes were sold on the premises.
Pharmacists were approached in person or surveyed via
mail. A maximum of two attempts were made to contact
each pharmacy. Questionnaires delivered to pharmacies
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via mail services included a prepaid envelope for return-
ing the questionnaire. When visiting pharmacies in
person by a member of the research team, the options
of ‘wait and collect’ and ‘collect at later date’ were
offered to all pharmacists. Only fully completed ques-
tionnaires were considered for the study. Consent was
obtained by means of an information letter accompany-
ing the questionnaire outlining its aims and content,
conﬁdentiality, right to not participate or withdraw, as
well as contacts of a minimum of three members of the
research team. All respondents agreed to participate by
returning a fully complete questionnaire. Only one
response was received by each pharmacy.
Questionnaire
Data collection was performed using a paper-based ques-
tionnaire, consisting of 26 questions (4 of which on
demographics). Question styles including closed, mul-
tiple response and open-ended questions were
employed. In questions using a Likert scale, participants
were asked to score statements on a ﬁve points scale,
that is, ranging from ‘very effective’ to ‘totally ineffective’
or from ‘strongly agree’ to ‘strongly disagree’. The ques-
tions contained in this research tool were developed by
the authors in collaboration with undergraduate stu-
dents. The themes were identiﬁed following a previous
survey conducted by the same team (unpublished)
aimed at establishing the aspects of e-cigarettes which
members of the public hoped to ﬁnd out more about.
As a consequence, the questionnaire was structured in
six sections. Section A aimed at surveying the current
use of any smoking cessation programme and NRTs
available on premises. Section B questioned respondents
on the current experience with e-cigarettes (eg, whether
e-cigarettes were sold on premises and adverse effects pre-
sented by users). Questions in Sections C and D aimed at
gauging the pharmacists’ perception of use, safety and
effectiveness, and of regulations of e-cigarettes, respect-
ively. Section E was regarding the type and content of
potential training on e-cigarettes for pharmacists. Section
F contained questions on demographics.
Pilot study
After ethics approval, a pilot study was conducted with
ﬁve pharmacists for content and face validation. The
outcomes of the pilot indicated that the questionnaire
was suitable for pharmacy professional, presented a sensi-
ble number of questions which could be completed
within a reasonable time, and required some minor
amendments of questions. The pharmacists involved in
the pilot were then excluded from the study to avoid any
type of bias.
Data analysis
Analysis of data was performed using Microsoft Excel.
Descriptive statistics were used to describe and summa-
rise the data highlighting the basic features of the study.
When analysing the responses, in questions regarding
the perception of safety and effectiveness of e-cigarettes
which were based on a Likert scale, the options ‘strongly
agree’ and ‘agree’ as well as ‘disagree’ and ‘strongly dis-
agree’ were, respectively, grouped together. Open-ended
questions were not analysed as these were not compul-
sory and only a minority of respondents added
comments.
RESULTS
Response rate and demographics
A total of 154 questionnaires were distributed across all
areas of London. From these, 92 questionnaires were
fully completed and returned. This resulted in an
overall 60% response rate. The demographics of the
population are summarised in table 1. On analysis of
results, no statistically relevant variation in responses was
observed when considering demographic data.
E-cigarettes users profile
E-cigarettes were shown to be sold on the premises of
73% (n=67) of community pharmacies responding to
the study. The majority of pharmacists identiﬁed the
most common form was nicotine-containing e-cigarettes
(97%, n=65). The most common age group to be identi-
ﬁed as purchasing e-cigarettes according to community
pharmacists was the ‘25–40 years old’ (90%, n=60), with
equal popularity among ‘18–24’ and ‘41–55 years old’
(each 4%, n=3). Adverse effects were presented to only
20% (n=19) of community pharmacists. Of these, 17%
(n=16) were ‘rarely’ presented with side effects and 3%
(n=3) of respondents described the frequency as ‘some-
times’. Side effects reported to pharmacists included
Table 1 Demographics of population
Number (n) Percentage (%)
Job type
Full time 45 48.9
Part time 5 5.5
Locum 34 36.9
Superintendents 3 3.2
Managers 5 5.5
Location
North 17 18.5
South 17 18.5
East 40 43.5
West 18 19.5
Years of practice (since registration)
0–5 27 29.3
6–10 36 39.1
11–15 15 16.3
16–20 5 5.5
>20 9 9.8
Gender
Male 61 66.3
Female 31 33.7
Total N=92.
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cough (n=10), dry mouth (n=7), sore throat (n=3) and
headache (n=1).
Respondents were required to rank ‘1’ (the most
important) to ‘5’ (the least important) the reasons why
users choose e-cigarettes. Some respondents (9%, n=8)
could not answer the question, due to lack of awareness
of the subject. From the remaining pharmacists (n=84),
its use as an ‘aid in stop smoking’ was ranked as the most
important (‘1’) by 56% (n=47). The use in ‘prevent
relapsing’ was ranked as ‘2’ (39%, n=33), whereas being
a ‘cheaper alternative’ was ranked as ‘5’ (43%, n=36),
thus deemed as the least important. Results are sum-
marised in table 2.
Pharmacists’ perception of effectiveness and safety
Participants were asked to rate the effectiveness of
e-cigarettes as a smoking cessation tool as compared to
NRTs and other support. Results are summarised in table 3.
In regard to ‘e-cigarettes are safe to inhale’, most com-
munity pharmacists showed no opinion (52%, n=47).
The majority of pharmacists (60%, n=65) disagreed with
the statement ‘e-cigarettes do not cause any adverse
effects’. With regard to ‘manufacturing of e-cigarettes is
unreliable’, half of the participants (51%, n=46) were
found to agree. Similarly, the following two statements
‘e-cigarette encourages smoking in non-smokers’ and
‘e-liquid in cartridges may be toxic’ found respondents in
agreement with 58% (n=52) and 61% (n=55), respect-
ively. For ‘the design of e-cigarettes encourage smokers to
give up smoking’, a signiﬁcant majority (81%, n=73)
agreed with it. Responses are summarised in ﬁgure 1.
Pharmacists’ perception of regulations
Overall, 97% (n=89) of respondents were in support of
future regulations of e-cigarettes. For the 97% who were
supportive, further potential beneﬁts were rated. The
main beneﬁts (rated ‘5, extremely beneﬁcial’) were ‘reas-
sured safety for e-cigarette users’ and ‘regulated as an
established NRT for smoking cessation’, with 72% (n=64)
and 55% (n=49), respectively. With regard to ‘preventing
the misuse of illegal substances’ and ‘increased proﬁt for
retail pharmacy’, responses were more normally distribu-
ted as summarised in ﬁgure 2.
All community pharmacists were required to choose
one aspect of e-cigarettes which they perceive should be
more tightly regulated. Excipients were selected by 42%
(n=37) of participants, nicotine concentration by 34%
(n=30), followed by eligibility and accessibility at 10%
(n=9) and 9% (n=8), respectively. Also, results from the
survey show that 63% (n=58) of pharmacists think that
the main disadvantages arising from the new regulation
will be the generation of a ‘black market’.
Training needs
Out of all responses, 83% (n=76) of community pharma-
cists stated that they were ready to stock and supply
e-cigarettes in their pharmacy, under new regulations.
To evaluate the perception of required training to meet
Table 2 Community pharmacists’ perception of reasons behind the use of e-cigarettes
Aid in stop
smoking
Use in
public
places
Prevent
relapse
Cheaper
alternative
Social/
recreational
use
n % n % n % n % n %
Ranked 1 (most important) 47 55.9 5 6.0 28 33.3 2 2.4 2 2.4
Ranked 2 25 29.8 8 9.5 33 39.3 5 6.0 13 15.5
Ranked 3 10 11.9 24 28.6 9 10.7 16 19.0 25 29.8
Ranked 4 1 1.2 30 35.7 11 13.1 25 29.8 18 21.4
Ranked 5 (least important) 1 1.2 17 20.2 3 3.6 36 42.8 26 30.9
Total 84 100 84 100 84 100 84 100 84 100
Table 3 Perception of the effectiveness of e-cigarettes in smoking cessation
Classic NRTs
(eg patch)
Newer NRTs
(eg Quickmist) E-cigarettes
GP and
pharmacist
counselling
Family and
support group
n % n % n % n % n %
Very effective 34 36.9 42 45.6 18 19.6 41 44.6 30 32.6
Effective 45 48.9 41 44.6 39 42.4 31 33.7 26 28.3
Slightly effective 12 13.1 8 8.7 22 23.9 18 19.5 24 26.1
Somewhat ineffective 1 1.1 1 1.1 8 8.7 2 2.2 11 11.9
Totally ineffective – – – – 2 2.2 – – 1 1.1
Unsure – – – – 3 3.2 – – – –
Total 92 100 92 100 92 100 92 100 92 100
GP, general practitioner; NRT, nicotine replacement therapy.
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potential future MHRA regulations on e-cigarettes, all
participants were asked to indicate the likely form and
content of training packages. Considering that each
participant could tick as many options as appropriate,
information packs were the most popular (88%, n=67),
followed by online tutorials at 67% (n=51), and profes-
sional developments workshops and video tutorials at
43% (n=33) and 33% (n=25), respectively. Participants
were also asked to score (1 to 10, with 10 being the most
important) the likely content of training packages.
A median grading analysis showed that safety was scored
in all cases as the most important (10 out of 10).
Counselling information, dosage instructions and
dealing with adverse effects had an average of 9 out of
10, whereas implementation into cessation programmes
scored 8 out of 10.
Figure 1 Perception of the safety and effectiveness of e-cigarettes.
Figure 2 Perception of potential benefits stemming from e-cigarettes regulations.
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DISCUSSION
Three-quarters of participants indicated e-cigarettes to
be sold on their premises. This demonstrates that many
pharmacies do not adhere with the current General
Pharmaceutical Council’s and the Royal Pharmaceutical
Society’s recommendations for pharmacies not to sell
and advertise e-cigarettes.19 20 The majority of respon-
dents are from small independent pharmacies, which
may have been driven to the decision of selling
e-cigarettes following major pharmacy chains doing so
in the UK.7 The most popular form of e-cigarettes is the
nicotine-containing one (97%, n=65). This popularity is
most probably due to the need to relieve craving and
consistent with the outcomes of the trial conducted by
Dawkins et al,22 which consisted of 86 smokers being ran-
domised to nicotine-containing (18 mg) e-cigarettes,
placebo or device given to hold. The outcomes indi-
cated that after 20 min, the use of nicotine-containing
e-cigarettes was superior in terms of relieving cravings.
The possibility of adverse effects was highlighted as
one of the primary reasons for enforcing e-cigarette reg-
ulations for the safety of users. However, respondents
reported to be not commonly presented with adverse
effects as the vast majority of them chose ‘never’ when
asked about user’s reports. Etter et al23 reported 21% of
e-cigarette users who stopped using e-cigarettes due to
the fear of e-cigarette-induced side effects, whereas
Goniewicz et al24 had only 17 (out of 179) users report-
ing adverse effects. The most common adverse effect
reported by community pharmacists was ‘cough’. Polosa
et al25 classiﬁed this frequent adverse effect as being a
result towards secondary exposure to humectants used
within e-liquid formulations. The excipient propylene
glycol has also been established to cause irritations
through inhalation. Headache and cough are also
reported as very common side effect of the use of
e-Voke.
More than half of the pharmacists perceived users
turn to e-cigarettes as an ‘aid in stop smoking’. This is
supported further by 44% (n=39) of respondents who
rated e-cigarettes as being ‘effective’ in promoting
smoking cessation. These views seem to be in line with
the perception of users who indicated to be using
e-cigarettes because they were safer than tobacco and to
quit smoking.23 Correlations can also be based on per-
ceptions of community pharmacists on the ‘design of
e-cigarettes encouraging smokers to give up smoking’, in
which 62% (n=56) chose ‘agree’, hence concluding that
the design of e-cigarettes is an effective characteristic in
promoting cessation as this targets the stimulus attach-
ment a smoker has.26
With regard to preventing relapse, the majority of
respondents (42%, n=38) chose ‘neutral’ and 27%
(n=25) chose ‘agree’ for the statement ‘nicotine delivery
via e-cigarettes is more efﬁcient than NRTs’. In addition
to this, e-cigarettes were perceived as effective as classic
NRTs (ie, patch, gum) and the newer NRTs (ie,
Quickmist, inhalator). In a 6-month study,16 abstinence
was compared between a nicotine patch and an
e-cigarette. The trial concluded with 7.3% attaining
abstinence through optimising an e-cigarette and 5.8%
attained abstinence through a NRT patch. Thus, this
shows the potential of e-cigarettes to attain increased
cessation numbers, which can be based on their ability
to provide nicotine through the same route as conven-
tional cigarettes. It is also noted that in comparison to
pharmacological tools, psychological support from
‘general practitioners and pharmacist counselling’ is
also perceived as ‘very effective’ according to 45%
(n=41).
In relation to ‘social/recreational use’, 31% (n=26) of
respondents ranked this as the least important for usage
of e-cigarettes. However, aspects of social and recre-
ational use can be determinant when non-smokers are
attracted to the vaping community. Regarding the state-
ment ‘e-cigarettes encourages smoking in non-smokers’,
almost half of respondents chose ‘agree’. According to
Bell and Keane,27 this promotes a negative opinion
regarding e-cigarettes and furthermore fears of uncon-
trolled use in non-smokers and in young adolescents.
Safety was a key concern expressed notably by commu-
nity pharmacists within this study. Participants revealed
concerns regarding the veriﬁed safety of e-cigarettes. In
regard to ‘e-cigarettes are safe to inhale’, the majority
either chose ‘neutral’ or ‘strongly agreed/agreed’. This
correlates to perceptions relating to ‘e-cigarettes do not
cause any adverse effects’, in which 60% chose ‘dis-
agree/strongly disagree’ and for ‘e-liquid in cartridges
may be toxic’, where 61% chose ‘strongly agreed/
agreed’. This is in line with the concerns expressed by
smoking cessation practitioners and reported by Hiscock
et al.10 The evidentiary conﬁrmation on negative percep-
tions on safety can also be linked to requests by respon-
dents of stricter regulations being imposed on
excipients. In line with respondents’ perception of
e-cigarettes on safety, half of the community pharmacists
chose ‘strongly agree/agree’ for the statement ‘manufac-
turing of e-cigarettes is unreliable’. Chen28 and
Avdalovic and Murin29 have related these types of per-
spectives to the unregulated procedures of manufactur-
ing, including being below standards of optimal quality,
reduced quality control and insufﬁcient evidence to
assure safety.
The concern on safety has been prevalent on the
support for regulations to be imposed in order to
control aspects of e-cigarettes. The support of MHRA
regulations to become obligatory was almost a unani-
mous consent in this study. Expressed opinions by many
included ‘to fully ensure the content in an e-cigarette do
not interact with patient medications’, ‘if available on
NHS then it is more for reaching’ and ‘gives us as phar-
macists the opportunity to engage those purchasing
these items, the same we would do with our regular cus-
tomers’. These perceptions enhance the hopes of com-
munity pharmacists to be more proactive in smoking
cessation while ensuring patient safety under enforced
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regulations. From those in support of regulations, major
beneﬁts were signiﬁcantly rated for ‘reassured safety for
e-cigarette users’ and for e-cigarettes to be ‘regulated as
an established NRT for smoking cessation’. Conversely,
those who were against regulations were primarily due to
perceptions on e-cigarettes being a tobacco product,
that is, ‘e-cigarettes are made by tobacco companies and
secondly it does not encourage you to quit at all’. This
type of perception can be the direct consequence of the
indecisiveness occurring in the EU parliament (and
MHRA) on regulations and e-cigarettes as being pro-
duced by tobacco companies, hence placing doubts on
e-cigarettes being a candidate to meet the criteria of
being a ‘medicine’.30
Respondents were further asked to choose one aspect
of e-cigarettes, which they felt should be more tightly
regulated. Excipients were selected by almost half of the
respondents, hence hinting the need for regulations to
ensure quality assurance and safety by manufacturers.
‘Nicotine concentration’ was instead selected by 34%
(n=30) of the respondents, ensuring that concentrations
do not lead to increased dependence or fatal toxicities.
Community pharmacists were also asked if they were
ready to stock and supply under future regulations. The
vast majority of respondents felt they were ready, hence
conﬁrming that community pharmacists are more com-
fortable to supply under enforced regulations. Despite
e-Voke has been licenced as NRT, to date, there has not
been an organised statement from the regulators as to
the role of e-cigarettes in smoking cessation nor a guid-
ance to the community pharmacists at the forefront of
this issue.
CONCLUSIONS
This study was implemented in order to gain an under-
standing of the community pharmacists’ perceptions of
e-cigarettes in terms of safety, reason for use, effective-
ness and regulations. The concerns outlined include
risks of unregulated excipients, faulty manufacturing
leading to suboptimal quality, uncontrolled concentra-
tions of nicotine and risks of adverse effects. In contrast,
e-cigarettes were distinguished as being an ideal candi-
date as an effective tool for cessation, distinctively sup-
ported by respondents. With the majority wishing to
stock and supply e-cigarettes under enforced regula-
tions, it is clear that community pharmacists believe
e-cigarettes can play a signiﬁcant role in affording
smoking abstinence and are ready to take new steps into
achieving higher quitting rates in smoking cessation.
The perceptions of community pharmacists are based
prominently on ensuring the upmost care and safety for
their patients. For these reasons, it is recommended that
regulations, other than on ad hoc basis as it has hap-
pened for e-Voke, are introduced in the near future.
This study is limited to a relatively small number of phar-
macies in the Greater London area; a similar study on
national scale is recommendable as its outcomes may
give a more general perception of e-cigarettes by
community pharmacists and gather useful information
for regulators. With the effects of control in conjunc-
tion with implementation of the pharmacist’s role in
an effective guidance, it is believed by many that
e-cigarettes do have a future within the community
pharmacy.
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